Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Santarus Jumps Last Hurdle for Submitting NDA on Key Blockbuster Drug Budesonide MMX (SNTS, $2.79)

Investment Opinion and Overview
For those of you who read my recent reports on Santarus, you will recall that I believe…
Read more…

An In-Depth Look at Santarus as it Develops a Promising Pipeline to Offset Patent Challenges to Existing Products (SNTS, $3.14)

Investment Overview
Santarus was founded to commercialize Zegerid for the treatment of gastrointestinal reflux disease (GERD) and ulcers. It competed in…
Read more…

Budesonide MMX's Potential in Ulcerative Colitis (SNTS, $3.18)

Investment Thesis
This report focuses on the ulcerative colitis market and particularly on budesonide MMX, an important new drug being developed…
Read more…

Rhucin in the Hereditary Angioedema Market Can Be A Meaningful New Product for Santarus (SNTS, $3.14)

Investment Thesis
This report is intended to highlight the potential for four current products and one in development for the treatment…
Read more…

Building a New Company on Zegerid's Ashes (SNTS, $2.24)

Investors are evaluating the impact on the earnings of Santarus following the recent launch of a generic to its key…
Read more…

Zegerid's Patents Are Ruled Invalid (SNTS, $5.36)

On April 14th, Santarus announced that a Court has ruled that five patents covering Santarus’ ZEGERID® (omeprazole/sodium bicarbonate) prescription products…
Read more…

Par Launches Generic Zegerid At Risk (SNTS, $4.55)

Par Pharmaceutical’s launched at risk a its generic version of Zegerid capsules, Santarus responded by launching its own authorized generic,…
Read more…

Details on Par's Challenge to Zegerid Parents (SNTS, $3.30)

Santarus has just anounced that Par has filed a paragraph IV challenge to Zegerid's patents. Depending on the outcome there…
Read more…

Santarus 2009 Analyst Day Highlights (SNTS, $1.98)

Management was quite optimistic about prospects for 2009 as both Zegerid and Glumetza are doing well. The company is looking…
Read more…

Update on Santarus (SNTS, $1.78)

Overview
I recently met with Debbie Crawford, Chief Financial Officer, and Martha Hough, Head of Investor Relations. I continue to feel…
Read more…